Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine
4 augusti 2016 uppdaterad av: GlaxoSmithKline
Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Mixed With Hib Vaccine in Healthy Infants, Followed by a Dose of the Same Vaccine Administered Simultaneously With One Dose of Oral Polio Vaccine (OPV)
This study will assess the immunogenicity and safety of the GlaxoSmithKline (GSK) Biologicals' (formerly SmithKline Beecham Biologicals') combined DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine administered in the 3rd, 5th, 11th month of life.
The last dose of DTPa-HBV-IPV/Hib will be given simultaneously with one dose of OPV vaccine.
Studieöversikt
Status
Avslutad
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
80
Fas
- Fas 3
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
2 månader till 3 månader (Barn)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
The inclusion criteria will be checked at study entry. If any of these criteria does not apply, the subject is not eligible for inclusion in the study.
- Healthy male and female subjects in the ≥12 and <16 weeks of life at the time of the first vaccination.
- Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- Written informed consent obtained from the parents/guardians of the infant after they have been advised of the risks and benefits of the study in a language which they clearly understood, and before performance of any study procedure.
Exclusion Criteria:
The exclusion criteria will be checked at study entry and at each following visit. If any of these criteria applies at study entry, the subject is not eligible for inclusion in the study. If any of these criteria becomes applicable during the study, the subject should be withdrawn.
- Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Administration of chronic immunosuppressants or other immune-modifying drugs within three months before vaccination).
- Administration of a vaccine not foreseen by the study within 30 days before each dose of the study vaccines and ending 30 days after.
- Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib disease.
- History of /or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib disease or infection.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Major congenital defects or serious chronic illness.
- History of seizures or of any neurological disease at study entry.
- Administration of immunoglobulins and/or any blood products since birth, or planned administration during the study period.
- Acute disease at the time of enrolment.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Grupp A
|
Tre doser administrerade intramuskulärt
One dose administered orally
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with antibody titres greater than or equal to cut off values
Tidsram: One month after the second dose and one month after the third dose of the primary vaccination course ( Month 3 and Month 9)
|
One month after the second dose and one month after the third dose of the primary vaccination course ( Month 3 and Month 9)
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with antibody titres greater than or equal to cut off values
Tidsram: Before the first dose ( Month 0 )
|
Before the first dose ( Month 0 )
|
|
Immunogenicity with respect to the components of the study vaccine in terms of antibody titers
Tidsram: Before the first dose (Month 0), one month after the second dose and one month after the third dose of the primary vaccination course ( Month 3 and Month 9).
|
Before the first dose (Month 0), one month after the second dose and one month after the third dose of the primary vaccination course ( Month 3 and Month 9).
|
|
Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with vaccine response
Tidsram: One month after the second dose, and one month after the third dose of the primary vaccination course (Month 3 and Month 9).
|
One month after the second dose, and one month after the third dose of the primary vaccination course (Month 3 and Month 9).
|
|
Immunogenicity with respect to the components of the study vaccine in terms of antibody titres greater than or equal to cut off values
Tidsram: One month after the second dose, and one month after the third dose of the primary vaccination course (Month 3 and Month 9).
|
One month after the second dose, and one month after the third dose of the primary vaccination course (Month 3 and Month 9).
|
|
Number of subjects with solicited and unsolicited adverse events
Tidsram: After each dose of the study vaccines (Month 0, Month 3 and Month 9) and overall
|
After each dose of the study vaccines (Month 0, Month 3 and Month 9) and overall
|
|
Number of subjects with serious adverse events
Tidsram: During the study period (Month 0 to Month 9)
|
During the study period (Month 0 to Month 9)
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 februari 2000
Primärt slutförande (Faktisk)
1 april 2001
Avslutad studie (Faktisk)
1 april 2001
Studieregistreringsdatum
Först inskickad
20 oktober 2011
Först inskickad som uppfyllde QC-kriterierna
20 oktober 2011
Första postat (Uppskatta)
24 oktober 2011
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
5 augusti 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
4 augusti 2016
Senast verifierad
1 augusti 2016
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Leversjukdomar
- Neuromuskulära sjukdomar
- Infektioner i centrala nervsystemet
- Hepatit, Viral, Human
- Hepadnaviridae-infektioner
- DNA-virusinfektioner
- Bakteriella infektioner
- Bakteriella infektioner och mykoser
- Gram-positiva bakteriella infektioner
- Actinomycetales infektioner
- Enterovirusinfektioner
- Picornaviridae-infektioner
- Ryggmärgssjukdomar
- Corynebacterium-infektioner
- Hepatit
- Myelit
- Hepatit B
- Difteri
- Polio
Andra studie-ID-nummer
- 217744/060
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Studiedata/dokument
-
Informerat samtycke
Informationsidentifierare: 217744/060Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisk studierapport
Informationsidentifierare: 217744/060Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datauppsättning för individuella deltagare
Informationsidentifierare: 217744/060Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datauppsättningsspecifikation
Informationsidentifierare: 217744/060Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Studieprotokoll
Informationsidentifierare: 217744/060Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .